Mucormycosis is a rapidly progressive and life-threatening invasive fungal disease with high morbidity and mortality rates despite treatment. It primarily affects immunocompromised patients such as those with organ and bone marrow transplantation and hematological malignancy and patients with diabetes, cancer, neutropenia, and skin trauma. In rare cases it also affects immunocompetent patients. Mucormycosis is caused by a group of molds called mucormycetes. Inhaling the spores of the molds can affect the lungs and sinuses, and the fungus may also invade the skin through wounds such as cuts, burns, scrapes, or other types of skin trauma.

Although rare, mucormycosis affects around 0.06 to 0.16 people per 10,000 globally each year. The threat of mucormycosis is growing with an increase in the population at risk, comprising mainly immunocompromised and critically ill patients. Mortality rates of 17% to 66% in patients with mucormycosis have been reported in recent studies. However, these can rise to over 90% in cases of disseminated infections.

The mucormycosis market is mainly driven by increase in occurrence of fungal infections, rise in incidence of immunological diseases, and greater access to a wide range of products. Furthermore, increase in government support for research & development and rise in awareness about fungal infections are fuelling the mucormycosis market. However, high cost of treatment is a major restraining factor for the mucormycosis market. The cost of treatment for mucormycosis is significant, with total costs much higher for mucormycosis patients when compared with matched controls at high risk of mucormycosis infection. Amphotericin B (AMB) formulations are the only licensed antifungal therapy known so far for mucormycosis, out of which the liposomal AMB (L-AMB) is widely used in Europe as the standard of care. However, L-AMB carries a risk of renal toxicity, which is related to the reduction of doses and finally discontinuations. Moreover, it is not available as an oral formulation. Thus, in order to fulfill unmet medical needs, more research is being carried out to develop new treatment methods for mucormycosis.

The mucormycosis market can be segmented based on species, diagnosis method, treatment, end-user,and region. Based on species, the mucormycosis market can be categorized into Rhizopus, Cunninghamella, Rhizomucor, Saksenaea, Apophysomyces, Lichtheimia, Mucor, and others. In terms of diagnosis method, the mucormycosis market can be classified into magnetic resonance imaging (MRI), computed tomography (CT), tissue biopsy, and others. Based on treatment, the mucormycosis market can be segmented into surgery, amphotericin B therapy, antifungal drugs, and others. The antifungal drugs segment can be further divided into isavuconazole, posaconazole, voriconazole, flucytosine, fluconazole, and others. In terms of end-user, the mucormycosis market can be categorized into hospitals & clinics, research organization, medical institutes, and others.

Based on region, the mucormycosis market can be classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds a significant share of the global mucormycosis market due to its advanced health care sector and a large patient population for mucormycosis. In the last few years, many antifungal drugs have lost their patients. For instance, Terbinafine products (Lamisil) lost their patient pool in 2017. As there is a limited number of oral preparations in the market, development and licensing of new drugs is a significant opportunity for the development of the market during the forecast period.

Europe holds a significant share of the global mucormycosis market. This is due to technological progressions in the area of surgical devices and rise in incidence of fungal infections. Governments of European countries have launched incentives schemes to boost the anti-infective drugs industry and reduce risk and cost for manufacturers. Another factor driving the mucormycosis market is the rising percentage of diabetes mellitus patients, mainly in the developed countries of Europe. The average prevalence rate of diabetes in Europe is around 9% of the adult population. The market in Asia Pacific is anticipated to expand at a rapid CAGR during the forecast period. This is due to various factors such as increase in prevalence of HIV and significant growth opportunities in the untapped market in emerging economies.

The key players in the global mucormycosis market are Abbott Laboratories, Biocon Limited, Cadila Pharmaceuticals Limited, Novartis AG, F. Hoffman La Roche, Merck Sharp and Dohme, Mylan Labs, Bristol Myers Squibb, Bayer AG, Lonza Group, Sanofi, Johnson & Johnson, Pfizer Inc., and Gilead Sciences.

This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.

The scrutiny of the various forces impacting the dynamics of the market, and key and associated industries, guides enterprises in understanding various consumer propositions. Our clients leverage these insights and perspectives to enhance customer experience in the fast-paced business environment.

All our insights and perspectives are broadly based on 4 Pillars or Stages: ASBC-S, which offer an elaborate and customizable framework for the success of an organization. The essence and the roles of these in organizational successes are highlighted below:

  • Agenda for CXOs: TMR, through the study, sets the tone for agendas that are pertinent to CEOs, CFOs, CIOs, and other CXO executives of businesses operating in the market. The perspectives help our clients to bridge the gap between agenda and action plan. TMR strives to offer guidance to CXOs to undertake mission-critical activities empowered by various business analysis tools, and boost the performance of the organizations. The perspectives guide you to decide on your own marketing mix that align well with the policies, visions, and mission.
  • Strategic Frameworks: The study offers how organizations are setting both short-term and long-term strategic plans. Our team of experts collaborate and communicate with you to understand these to make your organizations sustainable and resilient during tough times. The insights help them decide sustainable competitive advantage for each business units.
  • Benchmarking for Deciding Target Markets and Brand Positioning: The assessments in the study provides a scrutiny of marketing channels and marketing mix. Our various teams work synergistically with you to help identify your actual and potential direct, indirect, and budget competition areas. Additionally, the study helps you decide most effective budgets for various processes and promotional activities. Furthermore, the study guides you to set benchmarks for integrating people and processes with the 4Ps of marketing. Eventually, this will empower you to find out unique propositioning strategies and niches.
  • Business Composability for Sustainability (C-S): Constant strategy planning for sustainability characterizing our C-S framework in the report has become more relevant than before in the face of disruptions caused by pandemics, recessions, boom and bust cycles, and changing geopolitical scenario. The TMR study offers a high level of customization to help you achieve business composability. Composable enterprises are increasingly gaining the attention of CXOs in order to help them combat market volatility. Our analysts and industry experts help you wade through such uncertainties and guide you to become a smart sustainable business in entirety.

The study presents scrutiny of region-specific consumer and technology trends, including the most recent industry dynamics. These broadly cover but not limited to

  • North America, South America, and the Americas
  • Asia Pacific and Japan
  • Europe
  • Latin America
  • Middle East and Africa

The study offers data-driven insights and guidance of several aspects. Some of the more notable questions are:

  • What are the major recent trends that can influence the product life cycle and the RoI?
  • Which regulatory trends shape corporate-level, business-level, and functional-level strategies?
  • Which micromarketing initiatives of leading players will bring in investments?
  • What can be the best framework and tools for PESTLE analysis?
  • Which regions will witness rise in new opportunities?
  • Which are the game-changing technologies being used to capture new revenue streams in the near future?
  • Which operational and tactical frameworks are being adopted by various players in gaining customer loyalty?
  • What is the current and expected intensity of competition the market in the near future?

Disclaimer: This market research study is an ongoing effort and extreme care has been taken to maintain the highest levels of accuracy at all stages. However, in the light of the rapidly evolving business dynamics, some region-specific or other segment-specific changes may take time to be part of the study.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Mucormycosis Market